Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on September 10th, the Representative disclosed that they had bought between $1,001 and $15,000 in Insulet stock on August 18th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.
Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 8/28/2026.
- Purchased $15,001 – $50,000 in shares of Quanta Services (NYSE:PWR) on 8/27/2026.
- Purchased $15,001 – $50,000 in shares of Eaton (NYSE:ETN) on 8/27/2026.
- Sold $15,001 – $50,000 in shares of NIKE (NYSE:NKE) on 8/27/2026.
- Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of Wheaton Precious Metals (NYSE:WPM) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 8/26/2026.
- Purchased $1,001 – $15,000 in shares of The Goldman Sachs Group (NYSE:GS) on 8/26/2026.
- Sold $15,001 – $50,000 in shares of Lamar Advertising (NASDAQ:LAMR) on 8/25/2026.
- Sold $1,001 – $15,000 in shares of Phreesia (NYSE:PHR) on 8/25/2026.
Insulet Trading Down 2.0%
PODD traded down $2.72 during midday trading on Friday, reaching $131.96. 1,747,929 shares of the company’s stock traded hands, compared to its average volume of 1,624,980. Insulet Corporation has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The firm has a fifty day moving average of $152.36 and a two-hundred day moving average of $173.92. The stock has a market capitalization of $9.15 billion, a price-to-earnings ratio of 24.67, a P/E/G ratio of 1.04 and a beta of 1.08.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Talon Private Wealth LLC grew its holdings in shares of Insulet by 92.0% during the second quarter. Talon Private Wealth LLC now owns 5,124 shares of the medical instruments supplier’s stock valued at $780,000 after buying an additional 2,455 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in Insulet by 26.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 4,042 shares of the medical instruments supplier’s stock worth $615,000 after acquiring an additional 834 shares during the last quarter. Tidal Investments LLC lifted its position in Insulet by 24.1% in the 2nd quarter. Tidal Investments LLC now owns 16,773 shares of the medical instruments supplier’s stock valued at $2,554,000 after acquiring an additional 3,253 shares in the last quarter. WINTON GROUP Ltd lifted its position in Insulet by 149.6% in the 2nd quarter. WINTON GROUP Ltd now owns 9,065 shares of the medical instruments supplier’s stock valued at $1,380,000 after acquiring an additional 5,433 shares in the last quarter. Finally, Engineers Gate Manager LP boosted its stake in Insulet by 9.9% during the 2nd quarter. Engineers Gate Manager LP now owns 22,445 shares of the medical instruments supplier’s stock valued at $3,417,000 after purchasing an additional 2,025 shares during the last quarter.
Wall Street Analyst Weigh In
Several equities research analysts recently weighed in on PODD shares. Weiss Ratings lowered Insulet from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, June 24th. Wells Fargo & Company downgraded Insulet from an “overweight” rating to an “equal weight” rating and decreased their price objective for the stock from $255.00 to $144.00 in a report on Wednesday, August 5th. TD Cowen lowered their price objective on Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research report on Thursday, August 6th. Oppenheimer downgraded shares of Insulet from an “outperform” rating to a “market perform” rating in a research report on Wednesday, August 5th. Finally, Truist Financial reiterated a “hold” rating and issued a $153.00 price target (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $195.40.
Read Our Latest Report on Insulet
About Representative Cisneros
Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.
Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.
Insulet Company Profile
Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.
The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.
Featured Articles
- Five stocks we like better than Insulet
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
